Myocardial infarction
Pro Research Analysisby 
Searched over 200M research papers for "myocardial infarction"
Definition and Diagnostic Criteria for Myocardial Infarction
Myocardial infarction (MI) is defined as myocardial injury detected by abnormal cardiac biomarkers, especially cardiac troponins, in the context of acute clinical myocardial ischemia. Diagnosis requires a rise and/or fall in cardiac biomarkers with at least one value above the 99th percentile of the upper reference limit, along with evidence of acute ischemia such as symptoms, ECG changes, imaging evidence, or identification of a coronary thrombus 1269. The Fourth Universal Definition of MI emphasizes the importance of distinguishing myocardial injury from infarction and highlights the role of high-sensitivity troponin assays in clinical practice 69.
Epidemiology and Global Prevalence of Myocardial Infarction
MI remains a leading cause of death and disability worldwide. The global prevalence of MI is estimated at 3.8% in individuals under 60 years and 9.5% in those over 60, with prevalence increasing significantly with age 28. MI can be the first sign of coronary artery disease or occur repeatedly in those with established disease, and its incidence is often used as a proxy for the burden of coronary artery disease in populations 28.
Pathophysiology and Mechanisms of Myocardial Infarction
The most common cause of MI is thrombotic occlusion of a coronary artery following rupture of a vulnerable atherosclerotic plaque, leading to sudden ischemic death of myocardial tissue 410. Ischemia triggers metabolic and ionic disturbances, rapid loss of systolic function, and a wavefront of cardiomyocyte death. The heart’s limited regenerative capacity means that healing occurs through scar formation, driven by an inflammatory cascade and subsequent activation of fibroblasts . Multi-omics research is uncovering the complex molecular mechanisms and potential new biomarkers involved in MI pathogenesis .
Clinical Presentation and Classification
MI is traditionally classified as ST-elevation (STEMI) or non-ST-elevation (NSTEMI), though management strategies for both types have become more similar over time . Clinical presentation can range from minor, undetected events to catastrophic episodes causing sudden death or severe hemodynamic compromise 23. The diagnosis is supported by clinical symptoms, ECG changes, imaging, and biomarker evidence 127.
Advances in Diagnosis and Management
Recent decades have seen major improvements in MI outcomes due to better risk stratification, widespread use of invasive strategies, rapid revascularization (such as percutaneous coronary intervention or fibrinolysis), advanced antiplatelet and anticoagulant therapies, and secondary prevention with statins 35. Noninvasive imaging techniques, such as technetium-99m pyrophosphate scintigraphy, have improved diagnostic accuracy and allow for infarct sizing and localization .
Challenges and Future Directions
Despite advances, MI continues to pose significant challenges, especially in patients who develop complications like cardiogenic shock, which carries a high short-term mortality . There is a growing focus on prevention, early detection, and the use of omics technologies to identify new therapeutic targets and improve prognosis 510. Preventive strategies and safe treatment methods are especially important given the increasing prevalence of MI in older populations .
Conclusion
Myocardial infarction is a complex and prevalent cardiovascular event with significant global health impact. Advances in diagnostic criteria, understanding of pathophysiology, and management strategies have improved outcomes, but ongoing research and preventive efforts remain crucial to further reduce the burden of MI 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic